Cancer development is driven by the accumulation of alterations affecting the structure and
function of the genome. Whereas genetic changes disrupt the DNA sequence, epigenetic …

Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

PURPOSE Approximately 20% of patients with TP53-mutant myelodysplastic syndromes
(MDS) achieve complete remission (CR) with hypomethylating agents. Eprenetapopt (APR …

Epigenetics is dynamic and heritable modifications to the genome that occur independently
of DNA sequence. It requires interactions cohesively with various enzymes and other …

Curative cancer therapy remains a major challenge particularly in cancers displaying
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …

Venetoclax-based therapy can induce responses in approximately 70% of older previously
untreated patients with acute myeloid leukemia (AML). However, up-front resistance as well …

PURPOSE Magrolimab is a monoclonal antibody that blocks cluster of differentiation 47, a
don't-eat-me signal overexpressed on cancer cells. Cluster of differentiation 47 blockade by …

Aberrant DNA methylation plays a pivotal role in tumor development and progression. DNA
hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA …

Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …

Nonalcoholic steatohepatitis (NASH) is a progressive, inflammatory form of fatty liver
disease. It is the most rapidly rising risk factor for the development of hepatocellular …